News and developments


Discover all the information about the research, development and marketing of immunotherapy treatments and natural food supplements for a healthier life.

Probelte Pharma published the protocol for the PROACAROS phase III Beltavac® clinical trial in the TRIALS journal


Murcia, Spain — May 2025 Probelte Pharma has announced that the full protocol for the PROACAROS phase III clinical trial, designed to evaluate the efficacy and safety of Beltavac® subcutaneous…


Read more

Publication of findings on subcutaneous immunotherapy in the paediatric population


On 12 June, a study on the Beltavac® preparation was published in the Journal of Clinical Medicine, demonstrating the efficacy and good safety profile of subcutaneous immunotherapy in paediatric…


Read more

"Internationalisation Mentoring and Support” Programme


Probelte Pharma SLU, has received funding from the SME Internationalisation Mentoring and Support Programme. Among other costs, the company has used these funds to jointly fund dissemination and…


Read more

Probelte Pharma awarded the Plimsoll Certificate of Business Excellence 2023


Probelte Pharma SL, a manufacturer of allergen and bacterial immunotherapy products, has been awarded the Plimsoll Certificate of Business Excellence 2023. According to its latest…


Read more

Evaluation of the efficacy of subcutaneous immunotherapy with polymerised allergenic extract from Dermatophagoides pteronyssinus in patients with hypersensitivity to house dust mites


PROBELTE PHARMA has participated in the project entitled "EVALUATION OF THE EFFICACY OF SUBCUTANEOUSIMMUNOTHERAPY WITH POLYMERISED ALLERGENIC EXTRACT FROM DERMATOPHAGOIDES PTERONYSSINUS…


Read more

Murcia Chamber of Commerce XPANDE Programme


Probelte Pharma, S.L. has been a beneficiary of the European Regional Development Fund (ERDF), whose objective is to improve the competitiveness of SMEs. Thanks to this, we launched an…


Read more